Stonegate Initiates Coverage on Sirona Biochem Corp (TSX-V:SBM)
DALLAS, TX — October 17th, 2024 — Sirona Biochem Crop (TSX-V:SBM): Stonegate Capital Partners initiates their coverage on Sirona Biochem Corp (TSX-V:SBM).
Business Overview
Sirona Biochem Corp. is a Vancouver-based biotechnology company specializing in the stabilization and enhancement of carbohydrate-based molecules through proprietary carbohydrate chemistry, developed by its French subsidiary, TFChem. This innovation significantly improves the efficacy and safety of molecules, particularly in cosmetics and therapeutics. The Company’s platform has fueled the development of groundbreaking skincare innovations and therapeutic ingredients. Sirona operates on a licensing model, partnering with large organizations to commercialize its patented compounds, generating revenue through upfront payments, milestone payments, and royalties. Additionally, Sirona is planning its own commercial launch in select markets.
Key Programs Include:
• TFC-1067: Licensed to Allergan Aesthetics for dyschromia treatments
• GlycoProteM™: Sirona’s flagship anti-aging compound poised to enter the global skincare market.
Premier Anti-Wrinkle Solution: GlycoProteMim™ is Sirona’s most advanced product, a carbohydrate-based molecule targeting both surface and cellular-level skin aging processes. Clinical trials demonstrated significant results:
• 37% increase in skin density
• 54% reduction in oxidative stress and inflammation
• 75% of participants reported a visible reduction in wrinkles
• 25% increase in skin radiance
• 90% of participants noted improved quality of the skin.
These results make GlycoProteMim™ a standout in the premium skincare market. Sirona is positioning it as a top-tier anti-aging ingredient, engaging in strategic commercialization discussions with global partners across North America, South America, Europe, and Asia.
Key Licensing Agreement: In June 2022, Sirona entered into a global licensing agreement with Allergan Aesthetics (an AbbVie company) for its dark spot removing compound, TFC-1067. This agreement has accelerated Sirona’s entry into the skincare space, providing a blueprint for future product launches, including GlycoProteMim™.
________________________________________
Click Link for Full Report: https://stonegateinc.com/download/sbm-initiation/?wpdmdl=1100&refresh=6710002b4c4961729101867